Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 743 | 37.49 |
09:34 ET | 100 | 37.57 |
09:36 ET | 700 | 37.53 |
09:38 ET | 200 | 37.5 |
09:45 ET | 400 | 37.4633 |
09:48 ET | 100 | 37.47 |
10:01 ET | 100 | 37.67 |
10:10 ET | 100 | 37.67 |
10:15 ET | 400 | 37.79 |
10:17 ET | 100200 | 37.73 |
10:19 ET | 400 | 37.74 |
10:21 ET | 173 | 37.721 |
10:24 ET | 100 | 37.83 |
10:26 ET | 300 | 37.795 |
10:32 ET | 500 | 38.13 |
10:33 ET | 400 | 38.03 |
10:35 ET | 200 | 38.1 |
10:46 ET | 483 | 38.003 |
10:48 ET | 729 | 38.17 |
10:55 ET | 736 | 38.15 |
11:00 ET | 100 | 38.01 |
11:02 ET | 300 | 38.01 |
11:04 ET | 100 | 38.02 |
11:08 ET | 100 | 38.045 |
11:15 ET | 146 | 38.01 |
11:20 ET | 1158 | 37.98 |
11:22 ET | 100 | 37.985 |
11:24 ET | 200 | 38.04 |
11:29 ET | 525 | 38.1 |
11:31 ET | 291 | 38.002 |
11:33 ET | 100 | 38.075 |
11:38 ET | 100 | 38.085 |
11:40 ET | 224 | 38.04 |
11:44 ET | 100 | 38.115 |
11:45 ET | 100 | 38.192 |
11:51 ET | 1728 | 38.2 |
11:54 ET | 100 | 38.28 |
11:56 ET | 700 | 38.115 |
12:00 ET | 100 | 38.08 |
12:02 ET | 200 | 38.11 |
12:07 ET | 300 | 38.06 |
12:09 ET | 5036 | 38.05 |
12:12 ET | 572 | 38.01 |
12:16 ET | 100 | 38.04 |
12:18 ET | 4443 | 38.04 |
12:20 ET | 336 | 38.01 |
12:21 ET | 7233 | 37.85 |
12:25 ET | 300 | 37.84 |
12:27 ET | 100 | 37.83 |
12:30 ET | 300 | 37.84 |
12:32 ET | 100 | 37.89 |
12:38 ET | 400 | 37.76 |
12:50 ET | 571 | 37.49 |
12:52 ET | 1300 | 37.64 |
12:54 ET | 200 | 37.61 |
12:56 ET | 103 | 37.6 |
12:57 ET | 100 | 37.68 |
12:59 ET | 100 | 37.62 |
01:01 ET | 200 | 37.6 |
01:17 ET | 100 | 37.69 |
01:21 ET | 100 | 37.73 |
01:24 ET | 200 | 37.73 |
01:26 ET | 800 | 37.725 |
01:28 ET | 1700 | 37.76 |
01:32 ET | 300 | 37.83 |
01:33 ET | 100 | 37.81 |
01:35 ET | 4604 | 37.82 |
01:37 ET | 100 | 37.9 |
01:39 ET | 300 | 37.84 |
01:44 ET | 300 | 37.84 |
01:50 ET | 688 | 37.84 |
01:51 ET | 100 | 37.86 |
01:53 ET | 100 | 37.82 |
01:57 ET | 100 | 37.87 |
02:00 ET | 100 | 37.84 |
02:02 ET | 400 | 37.8 |
02:06 ET | 500 | 37.75 |
02:08 ET | 100 | 37.75 |
02:09 ET | 300 | 37.8 |
02:11 ET | 200 | 37.8 |
02:13 ET | 100 | 37.78 |
02:15 ET | 1000 | 37.8 |
02:31 ET | 1119 | 37.75 |
02:44 ET | 300 | 37.83 |
02:45 ET | 200 | 37.84 |
02:51 ET | 229 | 37.8007 |
02:54 ET | 300 | 37.84 |
02:56 ET | 500 | 37.89 |
03:00 ET | 200 | 37.825 |
03:02 ET | 500 | 37.82 |
03:03 ET | 900 | 37.87 |
03:05 ET | 2500 | 37.91 |
03:07 ET | 1500 | 37.905 |
03:12 ET | 4711 | 37.74 |
03:14 ET | 105 | 37.75 |
03:18 ET | 500 | 37.83 |
03:21 ET | 200 | 37.79 |
03:25 ET | 100 | 37.8 |
03:27 ET | 1100 | 37.84 |
03:30 ET | 500 | 37.82 |
03:32 ET | 100 | 37.81 |
03:36 ET | 249 | 37.83 |
03:38 ET | 700 | 37.86 |
03:39 ET | 567 | 37.85 |
03:41 ET | 200 | 37.85 |
03:43 ET | 3400 | 37.88 |
03:45 ET | 212 | 37.895 |
03:48 ET | 598 | 37.93 |
03:50 ET | 1857 | 38 |
03:52 ET | 2523 | 38.01 |
03:54 ET | 3475 | 38 |
03:56 ET | 6425 | 37.905 |
03:57 ET | 3686 | 37.85 |
03:59 ET | 6933 | 37.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -13.9x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.8x | --- |
Biohaven Ltd | 2.9B | -4.9x | --- |
Dyne Therapeutics Inc | 3.1B | -7.8x | --- |
IDEAYA Biosciences Inc | 2.9B | -19.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.